Drug resistance strongly impairs the efficacy of virtually every kind of anticancer therapy. This phenomenon is commonly fueled by intrinsic or acquired mechanisms. In this mini-review, focusing on BRAF-mutated melanoma as prototypical example, we analyze how recent studies that make use of single cell analysis identify the involvement of distinct transcriptional trajectories as the common thread at the basis of drug tolerance. The identification of these transcriptional trajectories provide a mechanistic basis for the development of both intrinsic and acquired drug resistance. These studies also suggest that hitting these transcriptional trajectories through personalized adaptive treatments can delay or abrogate the onset of drug resistanc...
BRAF inhibitors elicit rapid antitumor responses in the majority of patients with BRAF V600-mutant m...
The determination of individual cell trajectories through a high-dimensional cell-state space is an ...
peer reviewedTreatment options for patients with NRAS-mutant melanoma are limited and lack an effici...
Drug resistance strongly impairs the efficacy of virtually every kind of anticancer therapy. This ph...
Background The introduction of targeted therapies for the treatment of BRAF-mutant melanomas have im...
Continuous BRAF inhibition of BRAF mutant melanomas triggers a series of cell state changes that lea...
Abstract Treatment of BRAF‐mutant melanomas with MAP kinase pathway inhibitors is paradigmatic of th...
The introduction of v-raf murine sarcoma viral oncogene homolog B (BRAF) inhibitors in melanoma pati...
This systematic review investigated the literature on acquired v-raf murine sarcoma viral oncogene h...
We resolved a mechanism connecting tumor epigenetic plasticity with non-genetic adaptive resistance ...
BRAF inhibitor therapy may provide profound initial tumor regression in metastatic melanoma with BRA...
BACKGROUND:Kinase inhibition in the mitogen activated protein kinase (MAPK) pathway is a standard th...
Cellular heterogeneity is regarded as a major factor for treatment response and resistance in a vari...
Patients diagnosed with advanced-stage melanoma carrying NRAS-activating mutations face a dismal pro...
SummaryOnce melanomas have progressed with acquired resistance to mitogen-activated protein kinase (...
BRAF inhibitors elicit rapid antitumor responses in the majority of patients with BRAF V600-mutant m...
The determination of individual cell trajectories through a high-dimensional cell-state space is an ...
peer reviewedTreatment options for patients with NRAS-mutant melanoma are limited and lack an effici...
Drug resistance strongly impairs the efficacy of virtually every kind of anticancer therapy. This ph...
Background The introduction of targeted therapies for the treatment of BRAF-mutant melanomas have im...
Continuous BRAF inhibition of BRAF mutant melanomas triggers a series of cell state changes that lea...
Abstract Treatment of BRAF‐mutant melanomas with MAP kinase pathway inhibitors is paradigmatic of th...
The introduction of v-raf murine sarcoma viral oncogene homolog B (BRAF) inhibitors in melanoma pati...
This systematic review investigated the literature on acquired v-raf murine sarcoma viral oncogene h...
We resolved a mechanism connecting tumor epigenetic plasticity with non-genetic adaptive resistance ...
BRAF inhibitor therapy may provide profound initial tumor regression in metastatic melanoma with BRA...
BACKGROUND:Kinase inhibition in the mitogen activated protein kinase (MAPK) pathway is a standard th...
Cellular heterogeneity is regarded as a major factor for treatment response and resistance in a vari...
Patients diagnosed with advanced-stage melanoma carrying NRAS-activating mutations face a dismal pro...
SummaryOnce melanomas have progressed with acquired resistance to mitogen-activated protein kinase (...
BRAF inhibitors elicit rapid antitumor responses in the majority of patients with BRAF V600-mutant m...
The determination of individual cell trajectories through a high-dimensional cell-state space is an ...
peer reviewedTreatment options for patients with NRAS-mutant melanoma are limited and lack an effici...